Suppr
超能文献

Antisense oligonucleotides for atherosclerotic disease.

作者信息

Bajaj Archna, Rader Daniel J

机构信息

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Nat Med. 2020 Apr;26(4):471-472. doi: 10.1038/s41591-020-0835-2.

DOI:10.1038/s41591-020-0835-2

PMID:32251402

Abstract

摘要

相似文献

Antisense oligonucleotides for atherosclerotic disease.

Nat Med. 2020 Apr;26(4):471-472. doi: 10.1038/s41591-020-0835-2.

[Lipoprotein (a) - what to do?].

MMW Fortschr Med. 2018 Jan;160(1):46-49. doi: 10.1007/s15006-018-0092-1.

Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?

Curr Pharm Des. 2017;23(10):1562-1570. doi: 10.2174/1381612823666170125160108.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

Imaging with radiolabeled antisense oligonucleotides for the detection of intracellular messenger RNA and cardiovascular disease.

J Nucl Cardiol. 1999 May-Jun;6(3):345-56. doi: 10.1016/s1071-3581(99)90047-8.

Latest developments in the treatment of lipoprotein (a).

Curr Opin Lipidol. 2014 Dec;25(6):452-60. doi: 10.1097/MOL.0000000000000126.

Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty.

Circulation. 1996 Feb 15;93(4):772-80. doi: 10.1161/01.cir.93.4.772.

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.

Cardiovasc Drugs Ther. 2019 Dec;33(6):739-748. doi: 10.1007/s10557-019-06906-9.

Lipoprotein(a)-antisense therapy.

Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):51-56. doi: 10.1007/s11789-019-00096-2.

What's new on therapies for elevated lipoprotein(a).

Expert Rev Clin Pharmacol. 2019 Jun;12(6):495-499. doi: 10.1080/17512433.2019.1610391. Epub 2019 Apr 30.

引用本文的文献

The RNA revolution in medicine: from gene regulation to clinical therapeutics.

Anim Cells Syst (Seoul). 2025 Aug 25;29(1):523-543. doi: 10.1080/19768354.2025.2548253. eCollection 2025.

Single-particle rotational microrheology enables pathological staging of macrophage foaming and antiatherosclerotic studies.

Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2403740121. doi: 10.1073/pnas.2403740121. Epub 2024 Aug 5.

Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis.

Heart. 2022 Jan;108(1):61-66. doi: 10.1136/heartjnl-2021-319804. Epub 2021 Sep 30.

The Compelling Demand for an Effective PrP-Directed Therapy against Prion Diseases.

ACS Med Chem Lett. 2020 Nov 2;11(11):2063-2067. doi: 10.1021/acsmedchemlett.0c00528. eCollection 2020 Nov 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Antisense oligonucleotides for atherosclerotic disease.

Nat Med. 2020 Apr;26(4):471-472. doi: 10.1038/s41591-020-0835-2.

[Lipoprotein (a) - what to do?].

MMW Fortschr Med. 2018 Jan;160(1):46-49. doi: 10.1007/s15006-018-0092-1.

Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?

Curr Pharm Des. 2017;23(10):1562-1570. doi: 10.2174/1381612823666170125160108.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

Imaging with radiolabeled antisense oligonucleotides for the detection of intracellular messenger RNA and cardiovascular disease.

J Nucl Cardiol. 1999 May-Jun;6(3):345-56. doi: 10.1016/s1071-3581(99)90047-8.

Latest developments in the treatment of lipoprotein (a).

Curr Opin Lipidol. 2014 Dec;25(6):452-60. doi: 10.1097/MOL.0000000000000126.

Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty.

Circulation. 1996 Feb 15;93(4):772-80. doi: 10.1161/01.cir.93.4.772.

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.

Cardiovasc Drugs Ther. 2019 Dec;33(6):739-748. doi: 10.1007/s10557-019-06906-9.

Lipoprotein(a)-antisense therapy.

Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):51-56. doi: 10.1007/s11789-019-00096-2.

What's new on therapies for elevated lipoprotein(a).

Expert Rev Clin Pharmacol. 2019 Jun;12(6):495-499. doi: 10.1080/17512433.2019.1610391. Epub 2019 Apr 30.

引用本文的文献

The RNA revolution in medicine: from gene regulation to clinical therapeutics.

Anim Cells Syst (Seoul). 2025 Aug 25;29(1):523-543. doi: 10.1080/19768354.2025.2548253. eCollection 2025.

Single-particle rotational microrheology enables pathological staging of macrophage foaming and antiatherosclerotic studies.

Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2403740121. doi: 10.1073/pnas.2403740121. Epub 2024 Aug 5.

Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis.

Heart. 2022 Jan;108(1):61-66. doi: 10.1136/heartjnl-2021-319804. Epub 2021 Sep 30.

The Compelling Demand for an Effective PrP-Directed Therapy against Prion Diseases.

ACS Med Chem Lett. 2020 Nov 2;11(11):2063-2067. doi: 10.1021/acsmedchemlett.0c00528. eCollection 2020 Nov 12.

Suppr超能文献

Antisense oligonucleotides for atherosclerotic disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译